iTeos Therapeutics, Inc.

NasdaqGM:ITOS 株式レポート

時価総額:US$286.8m

iTeos Therapeutics マネジメント

マネジメント 基準チェック /34

iTeos Therapeuticsの CEO はMichel Detheuxで、 Aug2011年に任命され、 の在任期間は 13.25年です。 の年間総報酬は$ 5.77Mで、 10%給与と90%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.058%を直接所有しており、その価値は$ 166.91K 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と4.4年です。

主要情報

Michel Detheux

最高経営責任者

US$5.8m

報酬総額

CEO給与比率10.0%
CEO在任期間13.3yrs
CEOの所有権0.06%
経営陣の平均在職期間4.4yrs
取締役会の平均在任期間4.4yrs

経営陣の近況

Recent updates

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 15
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 15

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

Aug 11
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13
Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21
Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12
The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11
News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25
Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16
Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

iTeos Therapeutics EPS misses by $0.11

Nov 12

CEO報酬分析

iTeos Therapeutics の収益と比較して、Michel Detheux の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$121m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$6mUS$579k

-US$113m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

US$12m

Dec 31 2022US$11mUS$556k

US$97m

Sep 30 2022n/an/a

US$261m

Jun 30 2022n/an/a

US$330m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$6mUS$525k

US$215m

Sep 30 2021n/an/a

US$15m

Jun 30 2021n/an/a

-US$67m

Mar 31 2021n/an/a

-US$50m

Dec 31 2020US$17mUS$463k

-US$43m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$2mUS$460k

-US$27m

報酬と市場: Michelの 総報酬 ($USD 5.77M ) は、 US市場 ($USD 1.47M ) の同規模の企業の平均を上回っています。

報酬と収益: Michelの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Michel Detheux (57 yo)

13.3yrs

在職期間

US$5,767,774

報酬

Dr. Michel Detheux, Ph D, is Chairman of the Board at InnoSkel. He serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021.He has served as the Chief Executive Officer and Director...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Michel Detheux
President13.3yrsUS$5.77m0.058%
$ 166.9k
Matthew Gall
Chief Financial Officer4.4yrsUS$2.72m0.053%
$ 152.5k
Matthew Call
Chief Operating Officer5.3yrsUS$2.80m0.26%
$ 737.1k
Yvonne McGrath
Chief Scientific Officer2.8yrsデータなしデータなし
Adi Osovsky
Executive Vice President of Legal1.8yrsデータなしデータなし
Philippe Brantegem
Executive Vice President of Human Resources4.8yrsデータなしデータなし
David Feltquate
Chief Medical Officerless than a yearデータなしデータなし

4.4yrs

平均在職期間

50.5yo

平均年齢

経験豊富な経営陣: ITOSの経営陣は 経験豊富 であると考えられます ( 4.4年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Michel Detheux
President12.8yrsUS$5.77m0.058%
$ 166.9k
Ann Rhoads
Independent Director4.4yrsUS$317.52k0%
$ 0
David Hallal
Independent Chairman of the Board6.4yrsUS$416.42k0%
$ 0
Timothy Van Hauwermeiren
Independent Director6.4yrsUS$303.52k0%
$ 0
Matthew Vander Heiden
Member of Scientific Advisory Boardno dataデータなしデータなし
Tony W. Ho
Independent Director3.6yrsUS$305.02k0%
$ 0
Robert Iannone
Independent Director3.6yrsUS$308.27k0%
$ 0
David Lee
Independent Directorless than a yearUS$323.44kデータなし
Gordon Freeman
Chairman of Scientific Advisory Boardno dataデータなしデータなし
Benoit Van den Eynde
Member of Scientific Advisory Boardno dataデータなしデータなし
Florent Ginhoux
Member of Scientific Advisory Boardno dataデータなしデータなし
Roberta Zappasodi
Member of Scientific Advisory Boardno dataデータなしデータなし

4.4yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: ITOSの 取締役会経験豊富 であると考えられます ( 4.4年の平均在任期間)。